Publications by authors named "Deborah Robins"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

1,929

Total Likes

711

Extended Reach

2,551,433

Social Features

267
D
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
Sean Wharton, Thomas Blevins, Lisa Connery, Julio Rosenstock, Sohini Raha, Rong Liu, Xiaosu Ma, Kieren J Mather, Axel Haupt, Deborah Robins

September 2023

Videos about Article: user user

2 2 26 263 13 2 3 37 15

View All Article and Social Media Activity
O
Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.
Julio Rosenstock, Deborah A Robins, Kevin L Duffin, Jonathan M Wilson, Yanzhu Lin

Diabetes Obes Metab· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consumer Health Informatics to Advance Precision Prevention.
Oliver J Canfell, Leanna Woods, Deborah Robins, Clair Sullivan

Yearb Med Inform· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomised clinical trial: Design of the SYNERGY-NASH phase 2b trial to evaluate tirzepatide as a treatment for metabolic dysfunction-associated steatohepatitis and modification of screening strategy to reduce screen failures.
Raj Vuppalanchi, Rohit Loomba, Arun J Sanyal, Amir Nikooie, Yuanyuan Tang, Deborah A Robins

Aliment Pharmacol Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
Rohit Loomba, Mark L Hartman, Eric J Lawitz, Raj Vuppalanchi, Jérôme Boursier, Deborah A Robins

N Engl J Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.
Edward Pratt, Xiaosu Ma, Rong Liu, Deborah Robins, Tamer Coskun

Diabetes Obes Metab· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.
Edward Pratt, Xiaosu Ma, Rong Liu, Deborah Robins, Axel Haupt

Diabetes Obes Metab· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.
Juan P Frias, Stanley Hsia, Sarah Eyde, Rong Liu, Xiaosu Ma, Deborah Robins

Lancet· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist.
Olivier Benichou, Tamer Coskun, Malgorzata D Gonciarz, Parag Garhyan, Andrew C Adams, Deborah A Robins

Cell Metab· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Community input in a genomic health implementation program: Perspectives of a community advisory group.
Miranda E Vidgen, Katrina Cutler, Jessica Bean, David Bunker, Lindsay F Fowles, Deborah Robins

Front Genet· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a Genetics Education Program for Health Interpreters: A Pilot Study.
Miranda E Vidgen, Lindsay F Fowles, Satrio Nindyo Istiko, Erin Evans, Katrina Cutler, Deborah Robins

Front Genet· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis.
Jonathan M Wilson, Yanzhu Lin, M Jane Luo, Gary Considine, Amy L Cox, Deborah A Robins

Diabetes Obes Metab· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modifications of IL-6 by Hypochlorous Acids: Effects on Receptor Binding.
Lori I Robins, Erika K Keim, Deborah B Robins, John S Edgar, John S Meschke

ACS Omega· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Melissa K Thomas, Amir Nikooienejad, Ross Bray, Xuewei Cui, Jonathan Wilson, Deborah A Robins

J Clin Endocrinol Metab· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins, William C Roell, Jeffrey S Riesmeyer

Diabetes Obes Metab· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Charles Benson, Ross Bray, Deborah A Robins

Diabetes Obes Metab· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Mark L Hartman, Arun J Sanyal, Rohit Loomba, Jonathan M Wilson, Amir Nikooienejad, Deborah A Robins

Diabetes Care· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Deborah Robins

Lancet· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
Christopher P Recknor, Robert R Recker, Charles T Benson, Deborah A Robins, Alan Y Chiang

J Bone Miner Res· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Robert R Recker, Charles T Benson, Toshio Matsumoto, Michael A Bolognese, Deborah A Robins

J Bone Miner Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Conformational changes in the Arp2/3 complex leading to actin nucleation.
Avital A Rodal, Olga Sokolova, Deborah B Robins, Karen M Daugherty, Simon Hippenmeyer

Nat Struct Mol Biol· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Teriparatide: A bone formation treatment for osteoporosis.
Erik F Eriksen, Deborah A Robins

Drugs Today (Barc)· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis